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Short Communication
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ABSTRACT
Direct evidence confirming the hypothesis that a dysfunction of the mitochondrial respiratory chain (MRC)
underlies the pathogenesis of hyperlactatemia associated with highly active antiretroviral therapy (HAART)
is scarce. We studied mitochondrial DNA (mtDNA) content and MRC function in the skeletal muscle of an
HIV-infected patient during an episode of symptomatic hyperlactatemia. Skeletal muscle biopsy was per-
formed during the episode when the patient was symptomatic and 3 months later when the patient was clin-
ically recovered. Assessment of mitochondria was performed using histological, polarographic, spectrophoto-
metrical, and Southern blot and real time PCR DNA quantification methods. The histological study disclosed
extensive mitochondrial impairment in the form of ragged-red fibers or equivalents on oxidative reactions.
These findings were associated with an increase in mitochondrial content and a decrease in both mitochon-
drial respiratory capacity and MRC enzyme activities. Mitochondrial DNA content declined to 53% of con-
trol values. Mitochondrial abnormalities had almost disappeared later when the patient became asympto-
matic. Our findings support the hypothesis that MRC dysfunction stands at the basis of HAART-related
hyperlactatemia.
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HPERLACTATEMIA is observed in up to 10% of HIV-infectedpatients on antiretroviral therapy. In most cases, blood lac-
tate elevation is usually mild (less than 2-fold) and patients re-
main asymptomatic. With higher plasma lactate concentration,
patients may develop fatigue, weakness, abdominal pain, weight
loss, tachycardia, and/or exertional dyspnea. Occasionally, hy-
perlactatemia may lead to severe lactic acidosis and death.1,2
Due to their central role in intermediary metabolism, mito-
chondria could participate in such a metabolic imbalance. De-
spite the fact that mitochondrial dysfunction has been widely
investigated in other complications of antiretroviral therapy (as
zidovudine-related myopathy3 and lipodystrophy syndrome4),
few works have directly studied mitochondrial respiratory chain
(MRC) function in patients with hyperlactatemia.5–8 Although
a recent study9 has demonstrated mtDNA depletion in periph-
eral blood mononuclear cells (PBMCs) obtained from patients
with hyperlactatemia, the clinical repercussion of such a de-
pletion is uncertain because any abnormality in mitochondrial
DNA (mtDNA) in a pathogenic role must necessarily cause
overt MRC dysfunction.10
A 50-year-old HIV-1-infected man was admitted in May
2001 because of malaise, fatigue, weight loss, increasing ab-
dominal discomfort, and dyspnea for the previous 6 weeks. He
had been diagnosed with HIV infection in 1988 and treated with
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antiretroviral drugs for the past 8 years (including zidovudine
for 55 months, zalcitabine for 12 months, didanosine for 55
months, stavudine for 55 months, saquinavir for 20 months,
lamivudine for 12 months, ritonavir for 19 months, nelfinavir
for 28 months, and nevirapine for 12 months). At the time of
the study, he had been treated with stavudine 40 mg/12 hr, di-
danosine 400 mg/24 hr, indinavir 800 mg/12 hr, ritonavir 100
mg/12 hr, gemfibrozil 600 mg/12 hr, and allopurinol 300 mg/24
hr for at least the previous 6 months. Body fat changes con-
sisting of abdominal accumulation, gynecomastia, and lipoat-
rophy, as well as hypertriglyceridemia and hyperuricemia, had
been noticed in February 1999. On admission, the patient was
cachectic. Serum lactate was 49 mg/dl (normal: 5–22), but there
was no academia (pH 7.39, bicarbonate 21 mmol/liter). He had
mild abnormalities in liver and pancreas function tests. Sero-
logical markers for hepatitis C and B viruses were negative.
CD4 cell count was 450/mm3 and HIV-1 RNA was ,20
copies/ml. The patient was considered to have symptomatic hy-
perlactatemia. A first muscle biopsy was indicated, and all an-
tiretroviral drugs were immediately withdrawn. The condition
of the patient progressively improved and serum lactate and
liver and pancreas tests returned to normal concentrations 3
months after discontinuation of antiretroviral therapy. At this
time, when the patient was asymptomatic and was not receiv-
ing antiretroviral drugs, a second muscle biopsy was performed.
Four samples of quadriceps were obtained in each biopsy.
One was used for histological studies as explained elsewhere.11
A second sample was used to spectrophotometrically measure
enzyme activities of complexes I to V of MRC on muscle ho-
mogenate.12 Results were corrected by citrate synthase activity
in order to normalize for mitochondrial content.12 The third
sample was used to polarographically determine oxygen con-
sumption on fresh mitochondrial suspension13 using pyruvate-
malate, succinate, and ascorbate as substrates of complexes I,
II, and IV of MRC, respectively.14 Total DNA was extracted
by standard phenol-chloroform procedures from the fourth sam-
ple.
Rearrangements in mtDNA were examined by Southern blot
hybridization using a mitochondrial ND4 gene as the probe.15
For mitochondrial DNA quantification, the nuclear 18S rRNA
housekeeping gene and the highly conserved mitochondrial
ND2 gene were quantified separately by real time quantitative
polymerase chain reaction (PCR) (LightCycler FastStart DNA
Master SYBR Green I, Roche Molecular Biochemicals,
Mannheim, Germany). The PCR amplification of a 500-bp frag-
ment length of the 18S rRNA gene was performed by using the
forward 59-ACGGACCAGAGCGAAAGCAT-3 9 and the re-
verse 59-GGACATCTAAGGGCATCACAGAC-3 9 primers.
For the mitochondrial ND2 gene, the forward 59-GCCCTAGA-
AATAAACATGCTA-3 9 and the reverse 59-GGGCTATTCC-
TAGTTTTATT-39 primers were used for the amplification of
a 200-bp fragment length. The PCR reactions for mitochondr-
ial gene amplification contained 3 mM MgCl2, 0.25 pmol/ml of
each primer, and 10 ng of DNA in 20 ml of final volume. The
PCR reactions for nuclear gene amplification contained 2 mM
MgCl2, 0.3 pmol/ml of each primer, and 10 ng of DNA in 20
ml of final volume. The PCR amplification program consisted
of a single denaturation–enzyme-activation step of 10 min at
95°C, followed by 35 cycles (for 18S rRNA gene) and 29 cy-
cles (for the ND2 gene). Each cycle consists of a denaturation
step (2 sec at 95°C for the 18S gene and 0 sec at 94°C for the
ND2 gene), an annealing step (10 sec at 66°C for the 18S rRNA
gene and 10 sec at 53°C for the ND2 gene), and an extension
step (20 sec at 72°C for the 18S rRNA gene and 10 sec at 72°C
for the ND2 gene), with a temperature-transition rate of
20°C/sec. The fluorescent product was detected at the last step
of each cycle by single acquisition. The method used a double-
stranded DNA dye (SYBR Green I) to continuously monitor
product formation. The sensitivity of SYBR Green I detection
is limited by nonspecific product formation, which is monitored
by fluorescence acquisition at temperatures at which only spe-
cific products are double stranded. After amplification, a melt-
ing curve was acquired by heating the product at 20°C/sec to
95°C, cooling at 20°C/sec to 72°C for the ND2 gene and 76°C
for the 18S rRNA, and slowly heating it at 0.2°C/sec to 94°C
with continuous fluorescence collection. Melting curves were
used to determine the specificity of the PCR products. The re-
sults were expressed as the ratio of the mean mtDNA value of
duplicate measurements to the mean nuclear DNA value of du-
plicate measurements (ND2/18S rRNA).17 To also express
mtDNA content by organello, we divided the ND2/18S rRNA
quocient by citrate synthase activity. The second muscle biopsy
from the patient rendered enough biological material to perform
a Southern blot hybridization using a mitochondrial ND4 gene
probe in order to detect mtDNA deletions.4
All the results were expressed as the percentage with respect
to the mean (6 SD) of control values (100%) obtained from six
healthy men.
The first histological study showed 5–10% of ragged-red
fibers (RRF) or RRF equivalents and the presence of abundant
lipid droplets in 50% of myocytes. In the second biopsy, RRF
or equivalents had disappeared while only 5% of myocytes still
showed an abnormal amount of lipid droplets (Fig. 1).
A marked increase (335%) in mitochondrial content during
the symptomatic episode of hyperlactatemia was demonstrated.
After treatment withdrawal and disappearance of clinical symp-
toms, mitochondrial content decreased but still remained above
control values (177%, Fig. 2).
Enzyme activity decreased for all complexes of MRC dur-
ing the acute phase of hyperlactatemia. The decrease was spe-
cially marked for complexes III and V, which showed only 36%
and 11% of residual activity, respectively. Three months later,
a general recovery of activities was observed, returning all of
them into the control range (Fig. 2).
Regarding respiratory activity (Fig. 2), oxidation of all sub-
strates tested in the symptomatic phase was found to be de-
creased (21% for pyruvate, 41% for succinate, 54% for ascor-
bate). However, the second study of the patient was not
associated with a full recovery of respiratory activity.
Analysis of mtDNA relative abundance disclosed 47% of de-
pletion with respect to control values in the first study when
expressed by cell, which reached 83% when expressed by or-
ganello. Complete restoration of mtDNA content was ascer-
tained in the second biopsy, 3 months after highly active anti-
retroviral therapy (HAART) discontinuation (Fig. 3). The
Southern blot study of the second skeletal muscle specimen dis-
closed the presence of several mtDNA deletions of different
size (Fig. 3).
We have demonstrated mitochondrial proliferation, deficient
MRC complexes III and V activities, a general decay of mito-
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FIG. 1. Histological study of skeletal muscle during symptomatic hyperlactatemia (left) and after clinical and analytical 
recovery (right). First line: Gomori’s trichrome staining demonstrating ragged-red fibers (RRF, arrows). Second line: Cytochrome
c oxidase reaction demonstrating negative fibers (RRF equivalents, asterisks). Third line: Succinate dehydrogenase reaction
demonstrating hyperactive fibers (RRF equivalents, asterisks). Forth line: Oil red O staining demonstrating deposition of neutral
lipid droplets, which are more prominent in the first skeletal muscle biopsy (left).
chondrial respiratory capacity, and mtDNA depletion during a
symptomatic episode of hyperlactatemia in an HIV-infected pa-
tient. Mitochondrial DNA depletion was even more evident
when expressed by organello than by cell. A similar study per-
formed 3 months later, when the patient became asymptomatic,
showed a marked improvement in most of these mitochondrial
parameters. At that time, the patient was receiving no anti-
retroviral drugs, while the rest of the treatments were main-
tained. This fact argues against the hypothetical role of gemfi-
brozil in our pathological findings because although gemfibrozil
use has been described as causing decreased state 3 respiration
stimulated by malate-pyruvate,18 the drug was maintained dur-
ing the time that most of the abnormal mitochondrial parame-
ters returned to normal.
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FIG. 2. Results of biochemical studies of mitochondrial respiratory chain function. y-axis are arbitrary values, where 100 is
assigned to the mean of control group for each variable. Bars denote SD, which was obtained from six healthy men. CS, citrate
synthase; MRC, mitochondrial respiratory chain; C-I, complex I; C-II, complex II; C-III, complex III; C-IV, complex VI; C-V,
complex V.
FIG. 3. Results of genetic analysis. Left: Results of mtDNA quantification (by cell and by organello) using real time PCR
methodology (bars denote SD, which was obtained from six healthy men). CS, citrate synthase activity. Right: Radioactive South-
ern blot analysis of muscle mtDNA from the patient (second biopsy) and a healthy control. DNA samples were PvuII digested,
electrophoretically separated, and probed with the mitochondrial ND4 gene. Arrow indicates the wild-type mtDNA molecule
(right).
As a whole, our data confirm that multiple mitochondrial
dysfunction is involved in the pathogenesis of this syndrome
and are in accordance with two previous reports investigating
mitochondrial function of skeletal muscle in hyperlactatemic
HIV-infected patients. Gérard et al.6 biopsied skeletal muscle
in 6 of 14 patients with symptomatic hyperlactatemia and in
four of them found complex IV deficiency, with the residual
activity ranging from 16% to 36% of control values. Unfortu-
nately, there is a lack of data concerning the evolution after res-
olution of symptomatic hyperlactatemia in that study. More re-
cently, Church et al.8 reported abnormal mitochondrial
morphology and reduced activities (from 11% to 38%) for all
MRC complexes (from I to IV) in skeletal muscle of an HIV-
infected child with lactic acidosis and liver failure. Two months
after discontinuing treatment with nucleoside analogs, a marked
recovery was seen in both clinical status and MRC enzyme ac-
tivities. Two additional mitochondrial studies7,13 also found dif-
ferent MRC complex deficiencies on hepatic biopsies. Consis-
tent with all these facts, our demonstration that not only MRC
enzyme activities, but also respiration are concurrently dis-
turbed heightens the functional relevance of such MRC enzyme
deficiencies in HAART-related hyperlactatemia. However, our
documentation of skeletal muscle mitochondrial dysfunction in
the presence of hyperlactatemia does not necessarily mean that
this is the only tissue affected, or the main source of increased
lactate production in hyperlactatemic patients. In fact, Roge et
al.19 have shown that skeletal muscle function and response to
exercise remained relatively normal in patients with hyperlac-
tatemia.
Côté et al.9 demonstrated that mtDNA was significantly de-
pleted in PBMCs from HIV-infected patients with symptomatic
hyperlactatemia who were receiving HAART. The decrease in
mtDNA preceded the rise in venous lactate levels, an observa-
tion suggesting that hyperlactatemia is a consequence of
mtDNA depletion. However, that study lacks MRC functional
studies. Lactate is the product of anaerobic glycolysis. There-
fore, hyperlactatemia in normal aerobic conditions may indi-
cate mitochondrial dysfunction. In addition, if mtDNA deple-
tion plays a pathogenic role it must necessarily be via MRC
dysfunction, since mtDNA encodes only for certain subunits of
certain complexes constituting MRC. Therefore, polarographic
and spectrophotometrical studies of MRC must be the clue to
link genetic and clinical findings.10 The case described in the
present study, extensively evaluated from an MRC point of
view, is consistent with the hypothesis of Côté et al.9 that mi-
tochondrial toxicity stands at the basis of HAART-related hy-
perlactatemia.
An interesting aspect of our patient is that in addition to
mtDNA depletion, multiple mtDNA deletions were present.
One hypothetical mechanism to explain these gene defects, in
addition to g-polymerase inhibition, which causes mtDNA de-
pletion, could be the coexistence of inhibition of mitochon-
drial processing peptidases by protease inhibitors included in
HAART. Although not demonstrated to date, such a hypo-
thetical effect of HAART regimens has also been postulated
for mtDNA multiple deletions found in patients with lipody-
strophy.4,20 Irrespective of all these speculations, all the
above-mentioned data seem to confirm that mitochondrial
dysfunction is the basis of hyperlactatemia occurring during
HAART.
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